New therapeutic options for advanced forms of thyroid cancer.
about
Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation.FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes.Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.Novel targeted therapies and immunotherapy for advanced thyroid cancers.
P2860
Q35145140-CA196A40-4050-451A-9587-858682FD0EFFQ38768576-5232A31B-AE48-49BB-94A9-F187B28DAC70Q38842666-8DF6E423-0D4E-44DB-98A5-3883D683B4E2Q39146689-1C668072-2334-4CBA-A178-E8337A95EFE3Q39711361-DB21F26A-F82D-46F1-8461-1EB4269502C1Q49221322-ABD0E50B-65E5-460E-9819-B051C870D84EQ49887965-304F071D-9CDA-4CB0-9995-DD316766A536
P2860
New therapeutic options for advanced forms of thyroid cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New therapeutic options for advanced forms of thyroid cancer.
@en
type
label
New therapeutic options for advanced forms of thyroid cancer.
@en
prefLabel
New therapeutic options for advanced forms of thyroid cancer.
@en
P2860
P1476
New therapeutic options for advanced forms of thyroid cancer.
@en
P2093
Robert Smallridge
Victor Bernet
P2860
P304
P356
10.1517/14728214.2014.894017
P407
P577
2014-03-03T00:00:00Z